Related Experiment Videos
Melanoma: therapeutic options with recombinant interferons
Seminars in Oncology
|December 1, 1985
Summary
Recombinant interferons show promise for advanced melanoma, with objective regressions in 20% of patients. Complete responses, lasting over a year, highlight interferon therapy
Area of Science:
- Medical Oncology
- Immunology
Background:
- Melanoma incidence is rising, particularly in young adults.
- Effective treatments for advanced melanoma post-surgery are limited.
Purpose of the Study:
- Review the role of recombinant interferons in advanced melanoma treatment.
- Discuss ongoing and future clinical trials for interferon-based therapies.
Main Methods:
- Review of multiple clinical trials involving recombinant interferon alfa-2a and alpha-2b.
- Analysis of objective regression rates and response durability.
- Examination of trial designs for adjuvant and combination therapies.
Main Results:
- Objective regression observed in 20% of patients treated with recombinant interferons.
- Nearly one-third of responses were complete and durable (1-3+ years).
- Ongoing trials investigate adjuvant therapy and combinations with chemotherapy or antibodies.
Conclusions:
- Recombinant interferons are a valuable option in advanced melanoma treatment.
- Further research is needed to optimize interferon mechanisms and combination strategies.